Relma-cel

BIOLOGICAL5 trials

Sponsors

Shanghai Ming Ju Biotechnology Co., Ltd., Ruijin Hospital, Liangjing Lu

Conditions

Large B-cell LymphomaNon-Hodgkin LymphomaRelapsed or Refractory B-cell LymphomaSystemic Lupus ErythematosusSystemic Sclerosis

Phase 1

CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus

Shanghai Ming Ju Biotechnology Co., Ltd.Systemic Lupus Erythematosus

Start: 2023-02-24End: 2025-12-30Target: 24Updated: 2023-03-15

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus

Not yet recruitingNCT06297408

Shanghai Ming Ju Biotechnology Co., Ltd.Systemic Lupus Erythematosus

Start: 2024-03-31End: 2026-05-31Target: 24Updated: 2024-03-07

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

RecruitingNCT06414135

Liangjing LuSystemic Sclerosis

Start: 2024-06-12End: 2027-04-30Target: 6Updated: 2024-08-15

Phase 2

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

RecruitingNCT06479356

Shanghai Ming Ju Biotechnology Co., Ltd.Large B-cell Lymphoma, Non-Hodgkin Lymphoma

Start: 2024-08-15End: 2026-12-31Target: 12Updated: 2024-08-21

Phase 4

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

RecruitingNCT05806580

Ruijin HospitalRelapsed or Refractory B-cell Lymphoma

Start: 2023-05-01End: 2027-12-31Target: 8Updated: 2024-10-23

Related Papers

Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial.

2025-04-309 citations

Natural Killer-Cell Recovery in Patients Receiving CD19 CAR T-Cell Therapy: Dynamics and Clinical Significance

Blood2024-11-051 citations